|

Anti-PD-1 antibody Clinical Trials

6 actively recruiting trials across 2 locations

Also known as: PD-1 blocking antibody

Pipeline

Phase 1: 2Phase 2: 2Phase 1/2: 2

Top Sponsors

  • The Second Affiliated Hospital of Chongqing Medical University2
  • TiumBio Co., Ltd.1
  • Han weidong1
  • Chinese PLA General Hospital1
  • Boehringer Ingelheim1

Indications

  • Cancer4
  • Liver Disease2
  • Anti-PD-1 Antibody2
  • Chronic Hepatitis b2
  • Peg-IFNα1

Other4 trials

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A)
Phase 2
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)
Phase 2
Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies
Phase 1/2
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
Phase 1

Gilbert, Arizona1 trial

A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

Banner MD Anderson Cancer Center-Gilbert-55251

Phase 1

San Antonio, Texas1 trial

Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors

NEXT Oncology

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.